# Plateau Antibody Levels of a Recombinant (E.Coli) HPV Nonavalent Vaccine Versus Gardasil®9 in Young Women

> **NCT06197802** · — · ACTIVE_NOT_RECRUITING · sponsor: **Xiamen University** · enrollment: 392 (estimated)

## Conditions studied

- Cervical Cancer
- Condylomata Acuminata

## Interventions

- **BIOLOGICAL:** Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli)
- **BIOLOGICAL:** Gardasil®9

## Key facts

- **NCT ID:** NCT06197802
- **Lead sponsor:** Xiamen University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-12-30
- **Primary completion:** 2024-04-05
- **Final completion:** 2025-09-01
- **Target enrollment:** 392 (ESTIMATED)
- **Last updated:** 2025-07-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06197802

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06197802, "Plateau Antibody Levels of a Recombinant (E.Coli) HPV Nonavalent Vaccine Versus Gardasil®9 in Young Women". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06197802. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*